Answers are grounded in this paper and cite their sources.
This study's findings suggest that the TP53 and ATM comutation occurs in a subgroup of patients with NSCLC and is associated with an increased tumor mutation burden and response to ICIs. This suggests that TP53 and ATM comutation may have implications as a biomarker for guiding ICI treatment.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: